A prospective, randomised trial has shown that standard adjuvant chemotherapy is superior to capecitabine in the treatment of women with breast cancer aged 65 years or older; on the basis of the results of this study, capecitabine cannot be recommended in this setting.
Related Articles
Highlight
TURNING POINT – “The panel recommends that bisphosphonates are considered as part of the adjuvant breast cancer treatment in postmenopausal women…”
Cover Story
Angelo Di Leo: mapping the geography of breast cancer
Past events